adobe stock photos - Jiraporn Hemab Therapeutics A/S has completed an oversubscribed US$157m Series C financing round led by Sofinnova Partners to accelarate and expand its pipeline in bleeding disorders and thrombosis treatments.
Hemab Therapeutics A/S has completed an oversubscribed US$157m Series C financing round led by Sofinnova Partners to accelarate and expand its pipeline in bleeding disorders and thrombosis treatments.